Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes

July 7, 2021 updated by: Vanita Pais, The Hospital for Sick Children

Association Of Self Efficacy Levels, Resiliency Levels and Attachment Styles of Adolescents With Type 1 Diabetes and Their Caregivers

This project will assess self-efficacy levels(SE) ,resiliency and attachment style of adolescent with type 1 diabetes and their caregivers.SE and attachment style of patients and parents will be compared with each other as well as correlated with diabetes management as assessed by A1C and self inventory scale.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

170

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G1X8
        • The Hospital for Sick Children

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

T1DM patients aged 12 - 18 yrs from Sick Kids Diabetes Clinic and their primary caregiver.

Description

Inclusion Criteria:

  • T1DM patients age 12 - 18 yrs from Sick Kids Diabetes Clinic and a primary caregiver
  • T1DM > 1yr and able to communicate in English

Exclusion Criteria:

  • Families who cannot communicate in English (read, write, speak)
  • Diagnosed less than 1 year diabetes
  • Transient form of Diabetes (such as medication induced diabetes)
  • Exclude type 2 Diabetes and CFRD (cystic fibrosis related diabetes)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Examine the effects of patients' attachment styles (secure, mixed and fearful) on their type one diabetes management represented by A1C level
Time Frame: 25 minutes

The following tool will be used - Relationship Scale Questionnaire (RSQ): The 30-item RSQ is valid and reliable. 76 Re-test reliability of the RSQ ranged from 0.54 to 0.78 and correlation coefficients of RSQ and RQ ranged from 0.41 to 0.6191.

Adolescent Relationship Scale Questionnaire (A-RSQ): Sümer & Güngör (1999) used the A-RSQ and report validity of 0.7-0.95 as well as an internal consistency of 0.82.

25 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
a) Effect of attachment style on self efficacy level in patients.
Time Frame: 25 minutes
The following tool will be used - Self-Efficacy of Diabetes Self-Management (SEDM): This is a 10-item questionnaire that is used to assess perceived self-efficacy to preform diabetes care behaviours. Respondents are asked to score responses on a 1-10 Likert scale in which '1= not at all sure' to '10= completely sure'.
25 minutes
a) Effect of attachment style on self efficacy level in parents.
Time Frame: 25 minutes
The following tool will be used - Self-Efficacy of Diabetes Self-Management (SEDM): This is a 10-item questionnaire that is used to assess perceived self-efficacy to preform diabetes care behaviours. Respondents are asked to score responses on a 1-10 Likert scale in which '1= not at all sure' to '10= completely sure'.
25 minutes
b)Compare diabetes management self-efficacy and attachment style in patients.
Time Frame: 25 minutes
To compare diabetes self-efficacy (SEDM) in patients and their parents, paired t-tests will be calculated. In addition, to compare attachment styles in patients and their parents, McNemar's test will be used. Paired t-tests and McNemar's tests effectively take into account the correlations between parent-adolescent measures from the same family.
25 minutes
b)Compare diabetes management self-efficacy and attachment style in parents
Time Frame: 25 minutes
To compare diabetes self-efficacy (SEDM) in patients and their parents, paired t-tests will be calculated. In addition, to compare attachment styles in patients and their parents, McNemar's test will be used. Paired t-tests and McNemar's tests effectively take into account the correlations between parent-adolescent measures from the same family.
25 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vanita Pais, BSc,CDE, Sick Kids Hospital
  • Study Director: Christabelle Almeida, MSc,CDE, Sick Kids Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 18, 2019

Primary Completion (Actual)

January 30, 2020

Study Completion (Actual)

January 30, 2020

Study Registration Dates

First Submitted

March 9, 2018

First Submitted That Met QC Criteria

November 19, 2019

First Posted (Actual)

November 21, 2019

Study Record Updates

Last Update Posted (Actual)

July 8, 2021

Last Update Submitted That Met QC Criteria

July 7, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type1diabetes

3
Subscribe